Cargando…

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Introduction: Polymyxin B is a last-line therapy for carbapenem-resistant microorganisms. However, a lack of clinical pharmacokinetic/pharmacodynamic (PK/PD) data has substantially hindered dose optimization and breakpoint setting. Methods: A prospective, multi-center clinical trial was undertaken w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Zhenwei, Liu, Xiaofen, Du, Xiaoxing, Chen, Huiying, Zhao, Feng, Zhou, Zhihui, Wang, Yu, Zheng, Yang, Bergen, Phillip J., Li, Xi, Sun, Renhua, Fang, Li, Li, Wanzhen, Fan, Yaxin, Wu, Hailan, Guo, Beining, Li, Jian, Yu, Yunsong, Zhang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800617/ https://www.ncbi.nlm.nih.gov/pubmed/36588676 http://dx.doi.org/10.3389/fphar.2022.975066

Ejemplares similares

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Proteomic Response Revealed Signaling Pathways Involving in the Mechanism of Polymyxin B-Induced Melanogenesis
por: Zhang, Chuhan, et al.
Publicado: (2022)

Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
por: Liang, Qiqiang, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
por: Fan, Yaxin, et al.
Publicado: (2022)

Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin
por: Jin, Xi, et al.
Publicado: (2021)

Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance
por: Xu, Caifang, et al.
Publicado: (2022)

Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae
por: Tian, Yuan, et al.
Publicado: (2021)

Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis
por: Wu, Hailan, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against Streptococcus Pneumoniae
por: Li, Xin, et al.
Publicado: (2021)

Polymyxin B Combined with Minocycline: A Potentially Effective Combination against bla(OXA-23)-harboring CRAB in In Vitro PK/PD Model
por: Qu, Xingyi, et al.
Publicado: (2022)

Ceftazidime/Avibactam, Polymyxin or Tigecycline as a Rescue Strategy for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae in Bloodstream Infection: A Retrospective Cohort Study
por: Fang, Youling, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models
por: van der Meijden, Aart, et al.
Publicado: (2023)

Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
por: Lim, Tze-Peng, et al.
Publicado: (2018)

Risk Factors for Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections and Outcomes
por: Yuan, Youhua, et al.
Publicado: (2020)

Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil
por: Bartolleti, Flávia, et al.
Publicado: (2016)

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
por: Lan, Peng, et al.
Publicado: (2022)

Review and analysis of the overlapping threats of carbapenem and polymyxin resistant E. coli and Klebsiella in Africa
por: Venne, Danielle M., et al.
Publicado: (2023)

The Value of Neutrophil-To-Lymphocyte Ratio for Evaluating Blood Stream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae: A Retrospective Cohort Study
por: Wu, Heng, et al.
Publicado: (2022)

Resveratrol enhances the antimicrobial effect of polymyxin B on Klebsiella pneumoniae and Escherichia coli isolates with polymyxin B resistance
por: Liu, Li, et al.
Publicado: (2020)

Distribution of fluoroquinolone resistance determinants in Carbapenem-resistant Klebsiella pneumoniae clinical isolates associated with bloodstream infections in China
por: Zhan, Qing, et al.
Publicado: (2021)

The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-Resistant Klebsiella pneumoniae Infections
por: Jia, Xuedong, et al.
Publicado: (2023)

Genetic Diversity of Polymyxin-Resistance Mechanisms in Clinical Isolates of Carbapenem-Resistant Klebsiella pneumoniae: a Multicenter Study in China
por: Li, Ziyao, et al.
Publicado: (2023)

BL02, a phage against carbapenem- and polymyxin-B resistant Klebsiella pneumoniae, isolated from sewage: A preclinical study
por: Liang, Zhen, et al.
Publicado: (2023)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
por: Zhang, Jiayuan, et al.
Publicado: (2022)

2451. Synergistic Activity of Ceftazidime–Avibactam in Combination With Polymyxin B Against Carbapenem-Resistant Klebsiella pneumoniae
por: Borjan, Jovan, et al.
Publicado: (2018)

Analysis of a Refractory Case of Pediatric Meningitis Caused by Klebsiella pneumoniae Co-Resistant to Carbapenems and Polymyxins
por: Huang, Xu, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
por: Wang, Yu, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli
por: Jitaree, Kamonchanok, et al.
Publicado: (2019)

Outcomes and Risk Factors of Bloodstream Infections Caused by Carbapenem-Resistant and Non-Carbapenem-Resistant Klebsiella pneumoniae in China
por: Liang, Xiaoxue, et al.
Publicado: (2022)

Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
por: Lyu, Cheng, et al.
Publicado: (2020)

Non-clonal occurrence of pmrB mutations associated with polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae in Brazil
por: Rodrigues, Ana Claudia Souza, et al.
Publicado: (2019)

Antibacterial activity of Cinnamomum cassia L. essential oil in a carbapenem- and polymyxin-resistant Klebsiella aerogenes strain
por: Vasconcelos, Nathalie Gaebler, et al.
Publicado: (2020)

Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection
por: Wang, Peile, et al.
Publicado: (2023)

Molecular characterization of carbapenem-resistant and virulent plasmids in Klebsiella pneumoniae from patients with bloodstream infections in China
por: Yang, Yongqiang, et al.
Publicado: (2021)

A retrospective, comparative analysis of risk factors and outcomes in carbapenem-susceptible and carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infections: tigecycline significantly increases the mortality
por: Xiao, Tingting, et al.
Publicado: (2018)

In Vivo Development of Polymyxin B Resistance in Klebsiella pneumoniae owing to a 42 bp Deletion in the Sequence of phoQ
por: Xu, Qingqing, et al.
Publicado: (2020)

Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infection
por: Liu, Keh-Sen, et al.
Publicado: (2021)

Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection
por: Kong, Wenqiang, et al.
Publicado: (2023)

Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes
por: Gomes, Marisa Zenaide Ribeiro, et al.
Publicado: (2023)

Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China
por: Li, Yuanyuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ea6132koreh5btcb124119jlro